Blood Test Could Replace Tumor Biopsy for Personalized Neoantigen Vaccines, New Study Finds
EricTopol · x · 2026-09-29
Personalized neoantigen vaccines have already improved outcomes in refractory melanoma and shown promise in pilot studies of pancreatic cancer, glioblastoma, renal cell carcinoma and triple-negative breast cancer — but they required a tumor biopsy to identify antigens. A new study highlighted by Eric Topol shows the needed antigen information can now be obtained from a simple blood sample, potentially lowering the barrier for personalized cancer vaccines.
More from Research
- Why chirality matters for AI for Science: enantiomers behave differently in biology — madeofAjala · 2026-11-16
- RSS 2027 submissions open with FAQ clarifying two-stage review and negative-result bar — GeorgiaChal · 2026-11-16
- Mobile AI Factory: agents auto-build on-device SLMs with 19x less GPU time — pmttyji · 2026-11-16
- Berkeley paper: LLMs answer with stale values even when the update is in context — ombre-ai · 2026-11-16
- LatamGPT releases 178.4M-document open Latin American corpus on Hugging Face — OmarUFlorez · 2026-11-16
- Open-source TotalSegmentator spots a 42mm dilated aorta on a routine chest CT — MaziyarPanahi · 2026-11-16